Table 3 Therapeutic effects of MSC in human models of neurodegenerative diseases
Disease | NCT and Phase | Participants | Stage | Tissue source of MSC | Findings |
|---|---|---|---|---|---|
AD | NCT01297218 (I) | 9 | Completed | Allogeneic UCB | Feasible; safe; well tolerated |
NCT01696591 (Long-term follow-up of NCT01297218) | 9 | Unknown | Allogeneic UCB | Not yet published | |
NCT02054208 (I/IIa) | 45 | Completed | Allogeneic UCB | Not yet published | |
NCT03172117 (Long-term follow-up of NCT02054208) | 45 | Unknown | Allogeneic UCB | Not yet published | |
NCT03117738 (I/II) | 21 | Completed | Autologous AD | Not yet published | |
NCT04228666 (I/IIa) | 24 | Withdrawn | Autologous AD | Not yet reported | |
NCT02600130 (I) | 33 | Active | Longeveron | NA | |
NCT04855955 | 1 | Available | Autologous AD | NA | |
NCT02833792 (IIa) | 40 | Recruiting | Allogeneic (not mentioned) | NA | |
NCT04040348 (I) | 6 | Recruiting | Allogeneic UCB | NA | |
NCT02899091 (I/IIa) | 24 | Recruiting | Allogenic placenta | NA | |
NCT04684602 (I/II) | 5,000 | Recruiting | Allogenic UCB | NA | |
NCT04482413 (IIb) | 80 | Not yet recruiting | Autologous AD | NA | |
NCT01547689 (I/II) | 30 | Unknown | Allogenic UCB | NA | |
NCT02672306 (I/II) | 16 | Unknown | Allogenic UCB | NA | |
MS | NCT01745783 (I/II) | 26 | Completed | Autologous BM | Safety and efficacy |
NCT02326935 (I) | 2 | Terminated | Autologous AD | NA | |
NCT03799718 (II) | 20 | Completed | Autologous BM | Not yet published | |
NCT01854957 (I/II) | 20 | Recruiting | Autologous BM | NA | |
NCT01364246 (I/II) | 20 | Recruiting | Allogeneic UC | NA | |
NCT01377870 (I/II) | 22 | Completed | Autologous BM | Not yet published | |
NCT00395200 (I/II) | 10 | Completed | Autologous BM | Safe; feasible; positive therapeutic outcomes | |
NCT02403947 (I/II) | 1 | Terminated | Autologous BM | NA | |
NCT01895439 (I/II) | 13 | Completed | Autologous BM | NA | |
NCT01933802 (I) | 20 | Completed | Autologous BM | Safe; well tolerated; minor adverse events included transient fever and mild headaches | |
NCT02034188 (I) | 20 | Completed | Allogeneic UC | Feasible; safe | |
NCT02035514 (I/II) | 9 | Completed | Autologous BM | Not applicable | |
NCT02239393 (I) | 31 | Completed | Autologous BM | Safety and efficacy | |
NCT01056471 (I/II) | 30 | Completed | Autologous AT | Not yet published | |
NCT03326505 (I/II) | 60 | Completed | Allogeneic UC | Not yet published | |
NCT01730547 (I/II) | 15 | Recruiting | Autologous BM | Not yet published | |
NCT02495766 (I/II) | 8 | Completed | Autologous BM | Not yet published | |
NCT02166021 (II) | 48 | Completed | Autologous BM | Well-tolerated; induced short-term beneficial effects | |
NCT01606215 (I, II) | 21 | Completed | Autologous BM | Not yet published | |
NCT00781872 (I, II) | 24 | Completed | Autologous BM | Clinically feasible; safe; induced immunomodulatory effects | |
NCT03069170 (I) | 50 | Recruiting | Autologous BM | Not yet published | |
NCT02157064 (NA) | 221 | Unknown | Autologous AT | NA | |
PD | NCT01453803 (I/II) | 0 | Withdrawn | Autologous AT | NA |
NCT02184546 | 75 | Not yet recruiting | Autologous AT | NA | |
NCT04064983 | Unknown | No expanded access | Autologous AT | NA | |
NCT02611167 (I/II) | 20 | Completed | Allogeneic BM | NA | |
NCT00976430 | 5 | Terminated | Autologous BM | NA | |
NCT01446614 (I/II) | 20 | recruiting | Autologous BM | NA | |
NCT03550183 (I) | 20 | recruiting | Allogeneic UC | NA | |
NCT04506073 (II) | 45 | Not yet recruiting | Not mentioned | NA | |
NCT04928287 (II) | 24 | Not yet recruiting | Allogeneic AT | NA | |
NCT04995081 (II) | 60 | recruiting | Allogeneic AT | NA | |
NCT03684122 (I/II) | 10 | Not yet recruiting | Allogeneic UCB | NA | |
NCT04146519 (II/III) | 50 | Recruiting | Autologous (not mentioned) | NA | |
NCT05094011 (I) | 9 | Not yet recruiting | Autologous AT | NA | |
NCT04876326 (NA) | 15 | Recruiting | Autologous AT, Allogeneic UC | NA |